Generic Name and Formulations:
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; foam.
LEO Pharma Inc.
Indications for ENSTILAR:
Apply to affected areas once daily for up to 4 weeks; discontinue when control is achieved. ≥18yrs: max 60g every 4 days. Do not occlude.
<18yrs: not studied.
Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, or irritation occurs. Do not use on face, axillae, or groin, or if atrophy is present at treatment site. Avoid eyes, sun, UV light (eg, phototherapy). Flammable. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Vit. D3 derivative + topical steroid.
Systemic absorption potentiated by other corticosteroids.
Application site irritation and pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, psoriasis exacerbation.
Foam (60g)—1, 2
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room